Review of Prostate Anatomy and Embryology and the Etiology of Benign Prostatic Hyperplasia.
Aaron L, Franco OE, Hayward SW.
Urol Clin North Am. 2016 Aug;43(3):279-88. doi: 10.1016/j.ucl.2016.04.012.
Benign prostate hyperplasia and nutrition.
Das K, Buchholz N.
Clin Nutr ESPEN. 2019 Oct;33:5-11. doi: 10.1016/j.clnesp.2019.07.015. Epub 2019 Aug 12.
Management of Benign Prostatic Hyperplasia.
Kim EH, Larson JA, Andriole GL.
Annu Rev Med. 2016;67:137-51. doi: 10.1146/annurev-med-063014-123902. Epub 2015 Sep 2.
Benign prostatic hyperplasia.
Infante Hernández S, Gómez Rivas J, Moreno Sierra J.
Med Clin (Barc). 2024 Oct 25;163(8):407-414. doi: 10.1016/j.medcli.2024.04.014. Epub 2024 Jul 15.
Benign prostatic hyperplasia - what do we know?
Devlin CM, Simms MS, Maitland NJ.
BJU Int. 2021 Apr;127(4):389-399. doi: 10.1111/bju.15229. Epub 2020 Sep 24.
Benign Prostatic Hyperplasia.
Langan RC.
Prim Care. 2019 Jun;46(2):223-232. doi: 10.1016/j.pop.2019.02.003. Epub 2019 Apr 1.
Management of benign prostate hyperplasia: an overview of alpha-adrenergic antagonist.
Garg G, Singh D, Saraf S, Saraf S.
Biol Pharm Bull. 2006 Aug;29(8):1554-8. doi: 10.1248/bpb.29.1554.
Clinical value of prostate segmentation and volume determination on MRI in benign prostatic hyperplasia.
Garvey B, Türkbey B, Truong H, Bernardo M, Periaswamy S, Choyke PL.
Diagn Interv Radiol. 2014 May-Jun;20(3):229-33. doi: 10.5152/dir.2014.13322.
Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.
Lama J, Winograd J, Codelia-Anjum A, Bhojani N, Elterman D, Zorn KC, Chughtai B.
Curr Urol Rep. 2024 Oct 7;26(1):9. doi: 10.1007/s11934-024-01235-3.
The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.
Tchetgen MB, Oesterling JE.
Urol Clin North Am. 1995 May;22(2):333-44.
